SCOPE Papua New Guinea

The PNG SCOPE study is sponsored by the Burnet Institute and led by the PNG Institute of Medical Research (PNGIMR) and National Department of Health.

The goal of the study is to determine the operational feasibility and cost-effectiveness of introducing revised case management for patients with P. vivax malaria to inform national antimalarial policy and practice.  

The pre-implementation stage began in July 2023 with the first patient enrolled in stage 1 for treatment with G6PD testing and PQ on 11th October 2023.